Computational Analysis Reveals Molnupiravir’s Binding Dynamics Against Omicron Subvariants

Advanced Computational Methods Uncover Antiviral Binding Mechanisms

In a comprehensive computational investigation, researchers have employed sophisticated molecular modeling techniques to evaluate molnupiravir’s efficacy against emerging Omicron SARS-CoV-2 variants. The study utilized MM-GBSA (Molecular Mechanics, Generalized Born model, and Solvent Accessibility) methodology to examine free binding energies of protein-ligand complexes, providing crucial insights into the antiviral drug’s interaction with viral spike proteins.

Advanced Computational Methods Uncover Antiviral Binding Mechanisms
Protein Domain Architecture and Conservation Analysis
Molecular Docking Reveals Variant-Specific Binding Profiles
Molecular Dynamics Simulations Uncover Stability Patterns
Structural Flexibility and Binding Pocket Dynamics
Sustained Molecular Interactions Despite Conformational Changes
Implications for Antiviral Development and Variant Response

The research team implemented the primary module of the Schrödinger program to compute optimum binding energies, employing the VSGB 2.0 model with OPLS-AA force field alongside advanced solvent modeling. The computational framework incorporated physics-based modifications for π-π interactions, hydrophobic interactions, and hydrogen bonding self-contact interactions, creating a robust platform for analyzing molecular interactions at unprecedented detail.

Protein Domain Architecture and Conservation Analysis

Through detailed functional domain analysis, researchers identified the active regions of the spike protein crucial for interaction mechanisms. The target protein demonstrated high conservation with reference proteins, comprising 1268 base pairs homologous to Beta coronavirus spike protein. Structural examination revealed 16 domain sites in the target protein and 8 in homologous superfamily, with additional unregulated and site regions contributing to the protein’s functional complexity.

The domain analysis, accessible through InterPro database, provided essential context for understanding the evolutionary relationships and functional conservation across coronavirus variants, establishing a foundation for subsequent binding studies.

Molecular Docking Reveals Variant-Specific Binding Profiles

Using PyRx for molecular docking analysis, researchers calculated binding affinities between molnupiravir and spike protein variants. The BA.5 docked complex demonstrated a binding affinity of -5.70 kcal/mol, while BQ.1.1 showed -5.30 kcal/mol. The automated docking protocol evaluated five different interaction poses, calculating size, center, and bonding sites for each configuration.

Detailed 2D interaction analysis in Discovery Studio and Chimera revealed that molnupiravir formed stable, specific hydrogen bonds with key spike protein residues in both variants. For BA.5, strong hydrogen bonds were observed with Gly1042 and Gly1044, complemented by van der Waals contacts, carbon hydrogen bonds, and π-alkyl interactions with Tyr1045 and Val1038. The BQ.1.1 variant exhibited more extensive conventional hydrogen bonding with Tyr394, Arg353, Ser512, Thr428, and Asp426, utilizing both oxygen and nitrogen atoms for interaction.

The higher interaction density observed in BQ.1.1 complexes suggests a stronger overall binding affinity, consistent with the more favorable docking score obtained for this variant. This finding highlights the importance of variant-specific structural features in determining drug efficacy., according to expert analysis

Molecular Dynamics Simulations Uncover Stability Patterns

Extended molecular dynamics simulations provided critical data on system stability through RMSD (Root Mean Square Deviation) and RMSF (Root Mean Square Fluctuation) analyses, along with radius of gyration (Rg) and detailed ligand-protein interaction tracking., as additional insights

In BA.5 complexes, molnupiravir maintained stable binding within the active site throughout 100 ns simulations. The system reached equilibrium with protein RMSD of 10.46 Å and ligand RMSD of approximately 8.0 Å. Transient fluctuations between 40-75 ns stabilized from 80 ns onward, with the highest average RMSD (15.84 Å) recorded in residues 465-504 during the 45-60 ns window, indicating localized flexibility near the C-terminal region.

The BQ.1.1 variant presented a different stability profile, with receptor average RMSD of 13.0 Å (maximum 15.69 Å) demonstrating global stability. However, the ligand showed greater mobility with average RMSD of 18.72 Å, undergoing conformational shifts toward the β-core sheet region near the N-terminal site between 25-57 ns. This adaptive movement likely represents an energetically favorable conformational search, with the ligand maintaining receptor association throughout the trajectory despite increased flexibility.

Structural Flexibility and Binding Pocket Dynamics

RMSF analysis provided additional insights into regional flexibility across protein-ligand complexes. The BA.5 complex exhibited average RMSF of 1.7 Å, with fluctuations ranging from 0.7 Å to 5.2 Å. The BQ.1.1 complex, simulated over 50 ns, showed average RMSF of 1.61 Å with highest peaks reaching 4.2 Å.

Pronounced fluctuations occurred at residues 76, 103, and 203-279, along with terminal regions 518 and 599, primarily corresponding to loop regions. Ligand flexibility analysis revealed mean RMSF values of 5.38 Å for BA.5 and 4.34 Å for BQ.1.1 targets, suggesting significant intermolecular stability despite conformational dynamics.

The core, N-like domain, catalytic binding domain, and C-terminal domain contained substantial flexible loops, contributing to dynamic behavior that may facilitate proper ligand accommodation and catalytic mechanism execution.

Sustained Molecular Interactions Despite Conformational Changes

Interaction analysis confirmed that molnupiravir maintained crucial molecular contacts within active sites despite conformational flexibility. The helical motion of certain flexible bonds contributed to RMSD increases while preserving essential binding interactions.

In BA.5 complexes, molnupiravir established conventional hydrogen bonds and water-bridged interactions as predominant contact types. Key interacting residues included:

Arg1037 forming stable hydrogen bonds
Asp1039 contributing to binding stability
Cys1041, Gly1042, and Lys1043 maintaining continuous interactions
Gln1069 supporting binding through multiple contact types

BQ.1.1 complexes featured strong hydrogen bond interactions with Gly379, Asp426, Thr428, Ser512, Leu515, Thr545, Arg565, and Ala568, supported by hydrophobic interactions and water-mediated contacts. The ligand demonstrated adaptive binding behavior, temporarily relocating deeper into alternative binding cavities while establishing new interactions with Thr545, Arg565, and Ala568 through hydrophobic contacts and water bridges.

Additional stabilization occurred through salt bridge and hydrogen bond formation with Asp36 and Tyr34, indicating dynamic yet sustained engagement with the binding pocket. This adaptability suggests molnupiravir’s potential to maintain efficacy despite viral evolution and structural variations in emerging variants.

Implications for Antiviral Development and Variant Response

The comprehensive computational analysis provides valuable insights for ongoing antiviral development efforts. The demonstrated binding stability across Omicron subvariants, coupled with molnupiravir’s adaptive interaction profile, suggests continued potential effectiveness against evolving SARS-CoV-2 strains.

The research methodology establishes a robust framework for rapid computational assessment of existing therapeutics against emerging variants, potentially accelerating response times during future viral outbreaks. The detailed interaction maps and stability profiles contribute to structure-based drug design approaches, informing next-generation antiviral development strategies.

As viral evolution continues, such computational approaches will become increasingly vital for predicting therapeutic efficacy and guiding clinical decision-making in pandemic response scenarios.